Study in Subjects With Relapsed/Refractory Follicular Lymphoma
Status:
Recruiting
Trial end date:
2024-12-01
Target enrollment:
Participant gender:
Summary
This is a multicenter, double-blind, active-controlled, randomized, 3-stage, biomarker
enrichment design featuring early futility stopping and sample-size re-estimation with safety
run-in designed to evaluate the efficacy and safety of tazemetostat in combination with R2 in
subjects with R/R FL, who have completed at least 1 prior systemic chemotherapy,
immunotherapy, or chemoimmunotherapy.